November 2018

The State of Diabetes in Canada: The Human & Economic Costs of an Epidemic

11:30am-1:30pm | King Edward Hotel - 37 King Street East, Toronto

Right now, five million Canadians are living with diabetes and six million more are at risk of developing it soon. Since 2000, the number of Canadians with diabetes has doubled, such that now one Canadian is diagnosed with this progressive, chronic disease every three minutes.

By any definition, a disease affecting this proportion of our population is an epidemic.

Beyond the immeasurable human toll, treating diabetes costs our health-care system — and therefore every tax paying Canadian — $28 billion per year. Within a decade it will soar to $40 billion per year. Canada can no longer afford to ignore the impact of diabetes on individuals, families, our healthcare system and the economy.

With moderation by André Picard, join the EC for a discussion between Dr. Jan Hux, President & CEO of Diabetes Canada and Brian Hilberdink, President of Novo Nordisk Canada Inc. as they uncover the human and economic costs of this silent epidemic in Canada.

- Lunch will be served -

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

- For information about accessibility, please email peters@economicclub.ca
- Dietary restriction notes and meal requests must be submitted to peters@economicclub.ca by Wednesday, November 7, 2018

*The views expressed on the Economic Club platform are not that of the Economic Club or its affiliates but of the speakers alone and the organizations they represent*

Thank you to our Title Sponsors:

The State of Diabetes in Canada: The Human & Economic Costs of an Epidemic

André Picard

Health Columnist
The Globe and Mail

André Picard

André Picard is the health columnist at The Globe and Mail, where he has been a staff writer since 1987.

He is also the author of five books. His current bestseller is a collection of columns entitled “Matters of Life and Death: Public Health Issues in Canada.”

André is a graduate of the University of Ottawa and Carleton University and has received honorary doctorates from six universities, most recently the U of T.

Brian Hilberdink

Novo Nordisk Canada Inc.

Brian Hilberdink

Brian Hilberdink is the President of Novo Nordisk Canada. His 22-year career includes several years at the company’s headquarters in Denmark in the Global Marketing organisation, in addition to a variety of roles with Novo Nordisk in the U.S. Brian is an active contributor on the Board of Innovative Medicines Canada and BIOTECanada, and is also a founding member of the Diabetes Canada Impact Council.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given it experience and capabilities that also enable it to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries, and markets its products in more than 170 countries.

Dr. Jan Hux

President & CEO
Diabetes Canada

Dr. Jan Hux

Dr. Hux began her journey within the field of diabetes after graduating with a Doctor of Medicine degree from the University of Toronto and a Master of Science in Epidemiology from Harvard School of Public Health. She is a clinician-scientist and trained as a general internist and health services researcher.

For more than 20 years, Dr. Hux has had a long-standing affiliation with the Institute for Clinical Evaluative Sciences (ICES) in Ontario, as a trainee, scientist, chief operating officer and finally Deputy CEO and Senior Director, Public Relations and Partnerships. Within these positions, she was responsible for developing and leading the diabetes health services research portfolio.

She has published more than 100 peer-reviewed papers, currently holds an Adjunct Scientist appointment at ICES, and is an Adjunct Professor at the University of Toronto in the Departments of Medicine and Health Policy, Management and Evaluation. As an adjunct professor, Dr. Hux has taken the time to mentor female medical students, seeing them through medical school, residency and then on to becoming successful diabetes researchers.

Dr. Hux joined Diabetes Canada in 2012 as the Chief Scientific Advisor. In this role, she provided strategic leadership for the organization and in particular for the research and professional education portfolios, which includes the development and dissemination of Clinical Practice Guidelines. She has also acted as the organization’s media spokesperson. Her contributions to the management and strategic direction of the organization led to Dr. Hux’s appointment as President and CEO of Diabetes Canada in 2018.

Our Sponsors

Telus Interac Green Shield Canada